Bosentas Tablets — Bosentan 125 mg (20 Tablets) Cipla
Bosentas 125 (Bosentan) is a potent selective endothelin receptor antagonist used for the pathogenetic therapy of pulmonary arterial hypertension. The drug effectively blocks the vasoconstrictive action of endothelin-1, an excess of which causes thickening of the walls and narrowing of the lumen of the pulmonary vessels. Taking Bosentas 125 contributes to a reduction in pulmonary vascular resistance, improvement in cardiac output, and prevention of disease progression.
Manufacturer: Cipla. This dosage (125 mg) is the primary maintenance dose for most adult patients. Cipla guarantees high pharmaceutical equivalence to the original drug and full compliance with international safety standards.
Key Features:
- ✅ Maintenance Therapy: The optimal dosage for long-term control of pulmonary artery pressure after the adaptation period.
- ✅ Hemodynamic Stability: Allows for a significant reduction in the severity of shortness of breath and an improvement in the patient's WHO functional class.
- ✅ Systemic Effect: Prevents the development of fibrosis and vascular damage, which is critically important in systemic sclerosis.
Bosentas 125 is indicated for adult patients in the following conditions:
- 🔹 Pulmonary Arterial Hypertension (PAH): To improve exercise tolerance and reduce the risk of clinical worsening (functional class II–IV).
- 🔹 Reduction of Digital Ulcers: In patients with systemic sclerosis and an active form of digital vascular disease.
Sales Form: 1 pack contains 20 tablets (2 blisters of 10 pieces) in a 125 mg dosage.
⚠️ INSTRUCTIONS FOR USE:
- Dosage Regimen: The 125 mg dosage is usually prescribed as a maintenance dose. The standard regimen is 1 tablet (125 mg) twice daily (morning and evening).
- Dose Transition: Typically, this dosage is started after the first 4 weeks of taking the minimum dose of 62.5 mg.
- Method of Administration: Tablets are taken orally whole, without chewing, with water. Food intake does not affect the absorption of the drug.
- Important: Do not stop treatment suddenly; discontinuation of the drug should be gradual and carried out under medical supervision.
- ⛔ Pregnancy: Strict contraindication. Bosentan causes severe fetal malformations. A monthly pregnancy test is required for women of childbearing age.
- ⛔ Liver: Initially elevated levels of liver enzymes (ALT/AST more than 3 times above the norm).
- ⛔ Interaction: Forbidden to combine with cyclosporine A and glibenclamide.
- Breastfeeding (it is recommended to stop during therapy).
- Hypersensitivity to bosentan.
Patients taking Bosentas 125 should be under medical supervision:
- 🧪 Liver Function Tests: Risk of dose-dependent increase in transaminase levels (monthly blood biochemistry control is required).
- 🩸 Anemia: Possible decrease in hemoglobin levels, especially at the beginning of treatment.
- 💧 Fluid Retention: Appearance or worsening of peripheral edema (especially ankles and feet).
- 🧠 General Symptoms: Headache, nasal congestion, hot flashes, palpitations.
- 🤢 Gastrointestinal: Heartburn, nausea, indigestion.
Similar products
What Customers Say
No reviews yet
Your review can be the first!